Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing – All-In with Chamath, Jason, Sacks & Friedberg

Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing – All-In with Chamath, Jason, Sacks & Friedberg — Transcript

Market views

Bullish

LLY— Eli Lilly's GLP-1 drug has become the best-selling drug of all time with exceptional growth, surpassing Keytruda with over $8 billion in quarterly revenue growing at 80%
INDUSTRIALS— Eli Lilly's massive expansion plans with 10 new plants will create 20,000 construction jobs and 5,000-6,000 manufacturing jobs, benefiting industrial and construction companies
BRAIN— Brain diseases represent 40% of global human suffering with massive unmet medical needs, presenting significant opportunities for breakthrough therapeutics
MENTAL— Eli Lilly is starting studies for GLP-1 drugs in bipolar disorder and major depressive disorder, potentially transforming mental health treatment in 3-4 years

Bearish

BIOTECH— Biotech funding has collapsed from $20 billion annually to $5 billion, with half of publicly traded biotech companies trading at or below cash value
FOOD— The CEO of the leading obesity drug company criticizes processed food companies and the US food system, citing highly processed foods and chemicals as major health problems
MEDIA— Pharmaceutical advertising may face reduction as even pharma executives support limiting drug ads that annoy consumers and comprise significant media revenue
CHINA— Chinese pharma companies are heavily subsidized by the state, using a swarm model to copy and execute faster on derivative ideas through patent hacking

Not investment advice.

Mentioned

Market views